2-(1-甲基乙基)-2,8-二氮杂螺[4.5]癸烷-8-羧酸 1,1-二甲基乙酯 | 1061682-96-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 2-(1-甲基乙基)-2,8-二氮杂螺[4.5]癸烷-8-羧酸 1,1-二甲基乙酯
• 中文别名: 2-(1-甲基乙基)-2,8-二氮杂螺[4.5]癸烷-8-羧酸1,1-二甲基乙酯
• 英文名称: tert-butyl 2-isopropyl-2,8-diazaspiro[4.5]decane-8-carboxylate
• 英文别名: tert-butyl 2-propan-2-yl-2,8-diazaspiro[4.5]decane-8-carboxylate
• CAS: 1061682-96-9
• 化学式: C₁₆H₃₀N₂O₂
• 分子量: 282.426
• InChiKey: NNLMVXHZYAFNCO-UHFFFAOYSA-N

物化性质

• 沸点：
  359.6±35.0 °C(Predicted)
• 密度：
  1.03±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1-甲基乙基)-2,8-二氮杂螺[4.5]癸烷-8-羧酸 1,1-二甲基乙酯 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 2,8-Diazaspiro[4.5]decane, 2-(1-methylethyl)-, (2,2,2-trifluoroacetate) (1:2)
  参考文献：
  名称：

  PHENOTHIAZINES FOR TREATING MITOCHONDRIAL DISEASE

  摘要：

  The present disclosure describes phenothiazine compounds substituted by a bicyclic nitrogen-containing heterocyclic ring, and compositions and methods thereof. Such compounds can be useful in treating mitochondrial diseases in a subject, such as a human.

  公开号：

  WO2024050513A1
• 作为产物：
  描述：

  2,8-二氮杂螺[4.5]癸烷-8-羧酸叔丁酯 、 丙酮 在 三乙酰氧基硼氢化钠 、 溶剂黄146 作用下， 反应 16.0h， 以8%的产率得到2-(1-甲基乙基)-2,8-二氮杂螺[4.5]癸烷-8-羧酸 1,1-二甲基乙酯
  参考文献：
  名称：

  AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS

  摘要：

  本发明涉及作为Aurora蛋白激酶抑制剂的化合物。该发明还提供包含这些化合物的药用可接受组合物，以及在治疗各种疾病、状况和障碍中使用这些化合物和组合物的方法。该发明还提供了制备本发明化合物的方法。

  公开号：

  US20100137305A1

文献信息

• Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10023570B2

  公开（公告）日：2018-07-17

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10174027B2

  公开（公告）日：2019-01-08

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是通式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors
  申请人：Array BioPharma Inc.

  公开号：US11168090B2

  公开（公告）日：2021-11-09

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X1, X2, X3 and X4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.

  本文提供的是式 I 的化合物： 及其立体异构体和药学上可接受的盐或溶液，其中 A、B、D、E、X1、X2、X3 和 X4 具有说明书中给出的含义，它们是 RET 激酶的抑制剂，可用于治疗和预防可以用 RET 激酶抑制剂治疗的疾病，包括由 RET 激酶介导的疾病或紊乱。
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array BioPharma, Inc.

  公开号：US20170096425A1

  公开（公告）日：2017-04-06

  Provided herein are compounds of the General Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.
• SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array BioPharma Inc.

  公开号：US20200055860A1

  公开（公告）日：2020-02-20

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, D, E, X 1 , X 2 , X 3 and X 4 have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including diseases or disorders mediated by a RET kinase.